Fasudil attenuates myocardial fibrosis in association with inhibition of monocyte/macrophage infiltration in the heart of DOCA/salt hypertensive rats

Journal of Cardiovascular Pharmacology

Volumn 50, Issue 2, 2007, Pages 187-194

  Ishimaru, Kazuhiro ^a   Ueno, Hitoshi ^a   Kagitani, Satoshi ^a   Takabayashi, Daisuke ^a   Takata, Masanobu ^a   Inoue, Hiroshi ^a  

^a UNIVERSITY OF TOYAMA   (Japan)

Author keywords

Deoxycorticosterone acetate salt hypertensive rats; Fasudil; Inflammation; Myocardial fibrosis; Rho kinase inhibitor

Indexed keywords

DEOXYCORTICOSTERONE ACETATE; DRINKING WATER; FASUDIL; INTERLEUKIN 6; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROCOLLAGEN; PROCOLLAGEN 1; PROCOLLAGEN 3; PROTEIN C FOS; SODIUM CHLORIDE; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL INFILTRATION; CONTROLLED STUDY; DRUG INHIBITION; FIBROSING ALVEOLITIS; GENE EXPRESSION; HEART MUSCLE FIBROSIS; HYPERTENSION; MACROPHAGE; MALE; MONOCYTE; NEPHRECTOMY; NONHUMAN; PRIORITY JOURNAL; RAT; SYSTOLIC BLOOD PRESSURE;

1-(5-ISOQUINOLINESULFONYL)-2-METHYLPIPERAZINE; ANIMALS; BLOOD PRESSURE; CYTOKINES; DESOXYCORTICOSTERONE; ENDOMYOCARDIAL FIBROSIS; FIBRILLAR COLLAGENS; GENE EXPRESSION; HYPERTENSION; INFLAMMATION; MACROPHAGES; MALE; MINERALOCORTICOIDS; MONOCYTES; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-FOS; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER; SODIUM CHLORIDE, DIETARY;

EID: 34547945446     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e318064f150     Document Type: Article

References (45)

1. Weber KT, Sun Y, Guarda E. Nonclassic actions of angiotensin II and aldosterone in nonclassic target tissue (the heart): Relevance of hypertensive heart disease. In: Laragh JH, Brenner BM, eds. Hypertension: Pathophysiology, Diagnosis, and Management. 2nd ed. New York: Raven Press; 1995:2203-2223.
2. Fujisawa G, Dilley R, Fullerton MJ, et al. Experimental cardiac fibrosis: differential time course of response to mineralocorticoid-salt administration. Endocrinology. 2001;142:3625-3631.
3. Ramires FJ, Sun Y, Weber KT. Myocardial fibrosis associated with aldosterone or angiotensin II administration: attenuation by calcium channel blockade. J Mol Cell Cardiol. 1998;30:475-483.
4. Kagitani S, Ueno H, Hirade S, et al. Tranilast attenuates myocardial fibrosis in association with suppression of monocyte/macrophage infiltration in DOCA/salt hypertensive rats. J Hypertens. 2004;22:1007-1015.
5. Shimokawa H. Rho-kinase as a novel therapeutic target in treatment of cardiovascular diseases. J Cardiovasc Pharmacol. 2002;39:319-327.
6. Rolfe BE, Worth NF, World CJ, et al. Rho and vascular disease. Atherosclerosis. 2005;183:1-16.
7. Kataoka C, Egashira K, Inoue S, et al. Important role of Rho-kinase in the pathogenesis of cardiovascular inflammation and remodeling induced by long-term blockade of nitric oxide synthesis in rats. Hypertension. 2002;39:245-250.
8. Niggli V. Rho-kinase in human neutrophils: a role in signaling for myosin light chain phosphorylation and cell migration. FEBS Lett. 1999;445:69-72.
9. Nagatoya K, Moriyama T, Kawada N, et al. Y-27632 prevents tubulointerstitial fibrosis in mouse kidneys with unilateral ureteral obstruction. Kidney Int. 2002;61:1684-1695.
10. Shibuya M, Suzuki Y, Sugita K, et al. Effect of AT877 on cerebral vasospasm after aneurismal subarachnoid hemorrhage. J Neurosrg. 1992;76:571-577.
11. Shimokawa H, Seto M, Katsumata N, et al. Rho-kinase-mediated pathway induces enhanced myosin light chain phosphorylations in a swine model of coronary artery spasm. Cardiovasc Res. 1999;43:1029-1039.
12. Ikegaki I, Hattori T, Yamaguchi T, et al. Involvement of Rho-kinase in vascular remodeling caused by long-term inhibition of nitric oxide synthesis in rats. Eur J Pharmacol. 2001;427:69-75.
13. Satoh S, Kobayashi T, Hitomi A, et al. Inhibition of neutrophil migration by a protein kinase inhibitor for the treatment of ischemic brain infarction. Jpn J Pharmacol. 1999;80:41-48.
14. Satoh S, Yamaguchi T, Hitomi A, et al. Fasudil attenuates interstitial fibrosis in rat kidneys with unilateral ureteral obstruction. Eur J Pharmacol. 2002;455:169-174.
15. Numaguchi K, Egashira K, Takemoto M, et al. Chronic inhibition of nitric oxide synthesis causes coronary microvascular remodeling in rats. Hypertension. 1995;26:957-962.
16. Morikawa-Futamatsu K, Adachi S, Maejima Y, et al. HMG-CoA reductase inhibitor fluvastatin prevents angiotensin II-induced cardiac hypertrophy via Rho kinase and inhibition of cyclin D1. Life Science. 2006;79:1380-1390.
17. Liao X, Liu JM, Du L, et al. Nitric oxide signaling in stretch-induced apoptosis of neonatal rat cardiomyocytes. FASEB J. 2006;20:1883-1885.
18. Weber DS, Webb RC. Enhanced relaxation to the rho-kinase inhibitor Y-27632 in mesenteric arteries from mineralocorticoid hypertensive rats. Pharmacology. 2001;63:129-133.
19. Seko T, Ito M, Kureishi Y, et al. Activation of RhoA and inhibition of myosin phosphatase as important components in hypertension in vascular smooth muscle. Circ Res. 2003;92:411-418.
20. Davies SI, Reddy H, Caivano M, et al. Specifity and mechanism of action of some commonly used protein kinase inhibitor. Biochem J. 2000;351:95-105.
21. Satoh S, Utsunomiya T, Tsurui K, et al. Pharmacological profile of hydroxy fasudil as a selective rho kinase inhibitor on ischemic brain damage. Life Sci. 2001;69:1441-1453.
22. Shimokawa H, Takeshita A. Rho-kinase is an important therapeutic target in cardiovascular medicine. Arterioscler Thromb Vasc Biol. 2005;25:1767-1775.
23. Horton JW, Maass DL, Ballard-Croft C. Rho-associated kinase modulates myocardial inflammatory cytokines responses. Shock. 2005;24:53-58.
24. Frangogiannis NG. Targeting the inflammatory response in healing myocardial infarcts. Curr Med Chem. 2006;13:1877-1893.
25. Eddy A. Role of cellular infiltrates in response to proteinuria. Am J Kidney Dis. 2001;37(Suppl 2):S25-S29.
26. Funakoshi Y, Ichiki T, Shimokawa H, et al. Rho-kinase mediates angiotensin II-induced monocyte chemoattractant protein-1 expression in rat vascular smooth muscle cells. Hypertension. 2001;38:100-104.
27. Rocha R, Rudolph AE, Friedrich GE, et al. Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am J Physiol. 2002;283:H1802-H1810.
28. Ogata T, Miyauchi T, Sakai S, et al. Myocardial fibrosis and diastolic dysfunction in deoxycorticosterone acetate-salt hypertensive rats is ameliorated by the peroxisome proliferator-activated receptor-alpha activator fenofibrate, partly by suppressing inflammatory responses associated with the nuclear factor-kappa-B pathway. J Am Coll Cardiol. 2004;43:1481-1488.
29. Okumura T, Hayashi I, Ikezawa T, et al. Cyclooxygenase-2 inhibitors attenuate increased blood pressure in renovascular hypertensive models, but not in deoxycorticosterone-salt hypertension. Hypertens Res. 2002;25:927-938.
30. Eddy SS. Plasminogen activator inhibitor-1 and the kidney. Am J Physiol Renal Physiol. 2002;283:F209-F220.
31. Brown NJ, Nakamura S, Ma L, et al. Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo. Kidney Int. 2000;58:1219-1227.
32. Creemers E, Cleutjens J, Smits J, et al. Disruption of the plasminogen gene in mice abolishes wound healing after myocardial infarction. Am J Pathol. 2000;156:1865-1873.
33. Eitzman DT, McCoy RD, Zheng X, et al. Bleomycin-induced pulmonary fibrosis in transgenic mice that either lack or overexpress the murine plasminogen activator inhibitor-1 gene. J Clin Invest. 1996;97:232-237.
34. Wang YX, da Cunha V, Martin-McNulty B, et al. Inhibition of Rho-kinase by fasudil attenuated angiotensin II-induced cardiac hypertrophy in apolipoprotein E deficient mice. Eur J Pharmacol. 2005;512:215-222.
35. Satoh S, Ikegaki I, Toshima Y, et al. Effects of Rho-kinase inhibitor on vasopressin-induced chronic myocardial damage in rats. Life Sci. 2002;72:103-112.
36. Ishibashi T, Nagata K, Ohkawara H, et al. Inhibition of Rho/Rho-kinase signaling downregulates plasminogen activator inhibitor-1 synthesis in cultured human monocytes. Biochim Biophys Acta. 2002;1590:123-130.
37. Lee AA, Dillmann WH, McCulloch AD, et al. Angiotensin II stimulates the autocrine production of transforming growth factor-beta 1 in adult rat cardiac fibroblasts. J Mol Cell Cardiol. 1995;27:2347-2357.
38. Hattori T, Shimokawa H, Higashi M, et al. Long-term inhibition of Rho-kinase suppresses left ventricular remodeling after myocardial infarction in mice. Circulation. 2004;109:2234-2239.
39. Kim S, Iwao H. Activation of mitogen-activated protein kinases in cardiovascular hypertrophy and remodeling. Jpn J Pharmacol. 1999;80:97-102.
40. Slight SH, Joseph J, Ganjam VK, et al. Extra-adrenal mineralocorticoids and cardiovascular tissue. J Mol Cell Cardiol. 1999;31:1175-1184.
41. Ammarguellat FZ, Gannon PO, Amiri F, et al. Fibrosis, matrix metalloproteinases, and inflammation in the heart of DOCA-salt hypertensive rats: role of ET(A) receptors. Hypertension. 2002;39:679-684.
42. Sun Y, Zhang J, Lu L, et al. Tissue angiotensin II in the regulation of inflammatory and fibrogenic components of repair in the rat heart. J Lab Clin Med. 2004;143:41-51.
43. Zannad F, Alla F, Dousset B, et al. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Circulation. 2000;102:2700-2706.
44. Hayashi M, Tsutamoto T, Wada A, et al. Immediate administration of mineralocorticoid receptor antagonist spironolactone prevents post-infarct left ventricular remodeling associated with suppression of a marker of myocardial collagen synthesis in patients with first anterior acute myocardial infarction. Circulation. 2003;107:2559-2565.
45. Rossi GP, Di Bello V, Ganzaroli C, et al. Excess aldosterone is associated with alterations of myocardial texture in primary aldosteronism. Hypertension. 2002;40:23-27.